Fact Check: 'Compounded Tirzepatide Is Illegal Now'

'Compounded tirzepatide is illegal now' is not quite right. Here's what the law actually says, what's still permitted, and what patients should ask their providers.

"Compounded tirzepatide is illegal now" has become a common refrain online since the FDA removed tirzepatide from the shortage list in December 2024. Like most sweeping legal claims, it's partially true and partially misleading. This source check explains exactly what is and is not legal regarding compounded tirzepatide as of April 2026.

The careful legal picture: large-scale 503B outsourcing-facility production of compounded tirzepatide as an essentially-copy alternative to Zepbound and Mounjaro is no longer permitted. Personalized 503A compounding for individual patients with documented clinical need that the commercial product cannot meet remains legal. The practical market effect is that mass-market telehealth distribution of compounded tirzepatide has largely ended, while narrow personalized compounding continues.

The Law Actually Governing Compounding

U.S. compounding law is structured around two distinct regulatory regimes. Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional pharmacy compounding — a licensed pharmacist compounding a specific medication for a specific patient based on a specific prescription, for a clinical need that the commercially-available product cannot meet. Section 503B covers outsourcing facilities — larger operations that can compound in bulk under FDA oversight, subject to specific exceptions.

The shortage exception under 503B allows outsourcing facilities to produce essentially-copy versions of commercial drugs while those drugs are in shortage. When a drug is removed from the FDA shortage list, that exception ends. Tirzepatide was officially removed in December 2024, which ended the shortage-based 503B exception.

What's Still Legal

The key distinction is between mass-production-style compounding (which is over) and personalized compounding (which continues). The former was the commercial basis for the 2022-2024 telehealth boom. The latter is a much smaller, clinically-justified practice that has always been legal and remains so.

What "Documented Clinical Need" Means in Practice

For 503A personalized compounding of tirzepatide to be legitimate, there needs to be a documented clinical reason that the commercial product (Zepbound or Mounjaro) cannot meet the patient's need. Examples of legitimate clinical needs include documented allergies or intolerances to inactive ingredients in the commercial formulation, specific dose requirements that fall between commercial strengths, and other clinical circumstances documented in the medical record.

Preference for a different dose titration schedule, desire for a lower price, or general preference for a compounded product is not a documented clinical need. These are patient preferences, not clinical necessities, and they do not justify 503A compounding under the law.

The Enforcement Reality

The FDA and state pharmacy boards have enforcement authority over compounding operations. The March 2026 warning letters targeted specific operators alleged to be operating outside the permissible scope — mass-producing for general distribution, selling novel formulations, or marketing as FDA-approved. Compounding pharmacies operating within personalized 503A parameters were not the target.

Enforcement is not uniform across states or jurisdictions. State pharmacy boards have broad authority over in-state pharmacy operations, and their enforcement priorities vary. A compounding pharmacy operating within 503A boundaries in one state might face more or less scrutiny than a similar operation in another state, depending on the state board's enforcement posture.

What This Means for Patients

Patients who were previously receiving compounded tirzepatide through mass-market telehealth channels should assume that path is no longer available. The practical alternatives are brand-name Zepbound through LillyDirect or authorized telehealth (vial pricing starting at $299/month), personalized 503A compounding through a pharmacy that can document appropriate clinical need (narrow eligibility), or transitioning to another therapy (semaglutide, other options).

Patients still receiving "compounded tirzepatide" through a current telehealth provider should ask directly: is this 503A personalized compounding with documented clinical need, and what is that documented need? If the answer is unclear, the operation may be in a gray zone. See our related reporting on the March 2026 warning letters, which compounders still operate, and Zepbound vial pricing.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.